CLC bio Part of $ 10M EU PATHSEEK Project

 CLC bio Part of $ 10M EU PATHSEEK Project

AARHUS, Denmark--(BUSINESS WIRE)--CLC bio, the world's leading bioinformatics software developer, has been awarded a share of a EU-funded clinical research grant, PATHSEEK, worth $ 2 million out of a total project budget of $ 10 million.

As part of the grant, CLC bio will develop a user-friendly and computationally efficient solution for pathogen identification, host biomarker identification, pathogen variant characterization and molecular epidemiology in a clinical setting, as well as build a flexible computational back-end.

VP of R&D at CLC bio, Dr. Roald Forsberg, comments, "Current platforms in diagnostic laboratories are limited by the amount of time required for generating a result and by the limited sequence information available for pathogens. To overcome these limitations we're going to develop a disruptive diagnostic technological pathogen sequencing platform which utilizes our world-leading bioinformatics expertise to enable scientists to go from a patient sample to a result, in less than 48 hours."

CEO of CLC bio, Thomas Knudsen, adds, "From the start, it has been one of CLC bio's core strategies to do active research within the bioinformatics field and letting that research be a primary driver of our software development. We're currently part of and coordinating 10 different research projects, of which half are funded by the EU. This underlines our successful strategy and we plan to be part of even more research grants in the future."


PATHSEEK is a 3-year study led by Professor Judy Breuer at University College London, which will demonstrate the potential of next generation sequencing technologies in clinical microbiology labs, to enable the detection of pathogens directly from clinical samples and the early detection of drug resistant mutations. The study will look at infections with clear unmet clinical needs or which pose a global risk, including, HIV, Mycobacterium tuberculosis, hepatitis B (HBV) and C (HCV) and influenza A. PATHSEEK will also investigate two host pharmacogenomics biomarkers which predict response to therapy for HCV and HIV.

The partners in PATHSEEK include University College London (UK), Erasmus Universitair Medisch Centrum Rotterdam (NL), Oxford Gene Technology (UK), and CLC bio (DK).

About CLC bio


CLC bio
Lasse Görlitz
VP of Communications
Phone: +1 (617) 765-0687
E-mail: [email protected]

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.